Condition: Breast Cancer · Sponsor: Abramson Cancer Center at Penn Medicine
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
This description comes directly from the study's public registry record.
Lauren Bayne, PhD · 215-615-2367 · breastcancerclinicaltrials@pennmedicine.upenn.edu
Pauleen Sanchez, BA · 215-615-2367 · breastcancerclinicaltrials@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Georgetown University | Washington D.C., District of Columbia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt University | Nashville, Tennessee, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04841148